[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605069":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":53,"locations":63,"responsibleParty":81,"collaborators":30,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":30,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":107,"whyStopped":30,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: (Iron chelating agent group)","ACTIVE_COMPARATOR","Patients with beta-thalassemia who will receive conventional thalassemia management (iron chelating agent) only.",[13],"Drug: Iron chelating intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2: (Iron chelating agent + NAC group)","Patients with beta-thalassemia who will receive conventional thalassemia management (iron chelating agent) plus NAC (600 mg orally once daily) for 12 weeks.",[13,18],"Drug: N Acetyl cysteine 600mg",{"label":20,"type":10,"description":21,"interventionNames":22},"Group 3: (Iron chelating agent + ALA group)","Patients with beta-thalassemia who will receive conventional thalassemia management (iron chelating agent) plus ALA (600 mg orally once daily) for 12 weeks.",[13,23],"Drug: Alpha Lipoic Acid 600 MG Oral Tablets",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Iron chelating intervention","JADENU is indicated for the treatment of chronic iron overload due to blood transfusions.",[9,15,20],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"N Acetyl cysteine 600mg","N-acetyl cysteine (NAC) 600 mg will be administered orally once daily for 12 weeks.",[15],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Alpha Lipoic Acid 600 MG Oral Tablets","Alpha lipoic acid (ALA) 600 mg will be administered orally once daily for 12 weeks.",[20],[40,43,45,48,51],{"name":41,"affiliation":5,"role":42},"Sahar M El-Haggar, Professor","STUDY_DIRECTOR",{"name":44,"affiliation":5,"role":42},"Tarek M Mostafa, Professor",{"name":46,"affiliation":47,"role":42},"Basma A Mansour, Lecturer","Faculty of Medicine - Mansoura University",{"name":49,"affiliation":47,"role":50},"Mohammed A El hawary, Assistant Professor","PRINCIPAL_INVESTIGATOR",{"name":52,"affiliation":5,"role":50},"Mahmoud M Elkholy, Teaching Assistant",[54,59],{"name":55,"role":56,"phone":57,"phoneExt":30,"email":58},"Mahmoud M Elkholy, Master","CONTACT","01023997742","mahmoud.m_elkholy@yahoo.com",{"name":60,"role":56,"phone":61,"phoneExt":30,"email":62},"Basma A Mansour, PhD","01224445455","basma.atef@mans.edu.eg",[64],{"facility":65,"status":30,"city":66,"state":30,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Faculty of Pharmacy - Tanta University","Tanta","31511","Egypt","EG",{"type":71,"coordinates":72},"Point",[73,74],31.00192,30.78847,{"lat":74,"lon":73},[77,80],{"name":52,"role":56,"phone":78,"phoneExt":79,"email":58},"0020102397742","002",{"name":55,"role":50,"phone":30,"phoneExt":30,"email":30},{"type":50,"investigatorFullName":82,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Mahmoud Mohamed Elkholy","Teaching Assistant","100605069","phase-3-evaluating-the-effect-of-n-acetyl-cysteine-and-alpha-lipoic-acid-in-patients-with-beta-thalassemia-100605069",false,"NCT07157722","Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia","The Potential Role of N-Acetyl Cysteine or Alpha-Lipoic Acid as Adjuvant Therapies in the Treatment of Patients With Beta Thalassemia","NAC\u002FALA","Inclusion Criteria:\n\n* Patients with beta-thalassemia who will receive conventional thalassemia management.\n* Both genders.\n* Age ≥ 18 years old.\n\nExclusion Criteria:\n\n* Patients with familial hypercholesterolemia or history of premature atherosclerosis.\n* Patients with a prior history of significant cardiovascular diseases, such as coronary artery disease, myocardial infarction, or stroke.\n* Patients with severe renal dysfunction.\n* Patients with severe hepatic dysfunction.\n* Patients with diabetes.\n* Patients who will be non-compliant with the prescribed therapy.\n* Patients with other hemoglobinopathies.\n* Pregnant women.\n* Obese patients.\n* Patients who will receive antioxidant or anti-inflammatory medications.\n* Patients with inflammatory diseases, such as Systemic lupus erythematous, rheumatoid arthritis and inflammatory bowel disease.\n* Patients with oxidative stress related diseases, such as Alzheimer, Parkinson, COPD and cancer.","ALL","18 Years","70 Years",{"count":96,"type":97},66,"ESTIMATED","INTERVENTIONAL",[100],"PHASE3","The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.",[103],"Beta Thalassemia",[105,106],"NAC","ALA","NOT_YET_RECRUITING","2025-08-28",{"date":110,"type":111},"2025-09-05","ACTUAL",{"date":113,"type":97},"2025-08-30",{"date":115,"type":97},"2026-01-30",{"name":5,"class":6},1]